Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Endpoints on Merck kGAa
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5714)
•••
Comment by Noteableon Nov 21, 2022 12:52pm
106 Views
Post# 35115841

RE:Endpoints on Merck kGAa

RE:Endpoints on Merck kGAaNovember 21, 2022 - "German healthcare company Merck KGaA wants to ramp up its R&D productivity with the goal of launching a new drug, or tacking on a new indication to an approved med, every one and a half years."

https://endpts.com/merck-kgaa-spotlights-need-for-deals-to-shake-up-rd-with-external-partners-key-to-new-drugs/ 

19 minutes ago
20 Reads
Post# 35115748

RE:RE:Tactics used x Hedge Fund & MM to acquire shareholder stock

Whoever acquires ONCY will the one who makes the decision on who and where "pelareorep" will be manufactured, since those like Pfizer and Roche have both expanded their global manufacturing capacity of biological products in response to a global "in-shoring" move. 

Further biological manufiacturing capacity can be effectively expanded in North America with the expansion of new marketing opportunities beyond Europe, NA and Asia. 

November 21, 2022 - 11:34 AM
36 Reads
Post# 35115468

RE:RE:Tactics used x Hedge Fund & MM to acquire shareholder stock

The "Contract Manufacturer" is ONCY's current manufacturer who happems to be Merck KGaA's MilliporeSigma but could be whoever ONCY's acquirer decides upon - you twerp.

MerckKGaA and Pfizer are also ONCY's partners in ONCY's Phase 2 Bracelet-1 metastatic Breast Cancer study whose 16 week primary response rate assessment period was met at the end of October 2022.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities